Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301130 · ClinicalTrials.gov registry record · Phase 1
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 7
- Study locations
NCT02301130: Completed Phase 1 study of Advanced Solid Tumors, sponsored by Kyowa Kirin.
NCT02301130 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Kyowa Kirin. The registered enrollment target is 64 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (68% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02301130, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 7
- Study locations
Study Summary
Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Conditions Studied
Interventions
- BIOLOGICAL MEDI4736 (Durvalumab)
- BIOLOGICAL mogamulizumab
- BIOLOGICAL tremelimumab
Study Locations (7)
California
- The Angeles Clinic - Los Angeles
- UCLA Hematology & Oncology Clinic - Los Angeles
Connecticut
- Yale Cancer Center - New Haven
Florida
- H. Lee Moffitt Cancer Center - Tampa
Georgia
- Georgia Cancer Center - Augusta
New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-11-26 |
| Est. Completion | 2018-03-05 |
| Phase | Phase 1 |
What the finished NCT02301130 record still lists
NCT02301130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which MEDI4736 (Durvalumab) is the first listed.
NCT02301130 lists 7 locations in 6 states (California, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT02301130 about?
NCT02301130 is a clinical study titled "Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors". Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
What is the current status of trial NCT02301130?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2014-11-26. Estimated completion is 2018-03-05.
What conditions does trial NCT02301130 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT02301130?
The interventions under investigation include: MEDI4736 (Durvalumab) (BIOLOGICAL), mogamulizumab (BIOLOGICAL), tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02301130?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02301130 being conducted?
This trial has 7 study locations across California, Connecticut, Florida, Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02301130's enrollment target sits among peer trials
64 96th of 144 higher than 49 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI